Ongoing Trial of Penticton Councillor Accused of Past Youth Sexual Abuse
A current city councillor from Penticton is undergoing a trial in Sarnia, Ontario, facing...
Nobody said building a fusion power plant would be easy. Physicists and engineers have been working for decades to crack the problem. But over the last year or so, fusion startup Zap Energy took a deeper look at its pathway to a working power plant and decided that it would be quicker to build a fission
A model is only as good as its data, and for Roman Teslyuk, the data wasn’t coming fast enough. “I hate delays,” Teslyuk, founder and CEO of Earth AI, told TechCrunch. For the last few years, Earth AI has been searching for critical minerals like copper, platinum, and palladium in parts of Australia where no
The race to secure electricity for AI models has reached new heights: Meta has signed an agreement with the startup Overview Energy that could see a thousand satellites beam infrared light to solar farms that power data centers at night. In 2024, Meta’s data centers used more than 18,000 gigawatt-hours of electricity — roughly enough
The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug's medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration's controlled
Founders building in the healthcare space can’t just build fast and break things. Timelines stretch longer, stakes are higher, and success depends on navigating systems that reward rigor over speed. That’s exactly the reality Robhy Bustami, co-founder and CEO of BioticsAI, has been building in. His company is developing an AI copilot for ultrasound that
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk and Eli Lilly 's blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use
More than 20,000 people have started taking Eli Lilly 's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly's once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk's Wegovy pill. Investors have been closely
Pharma thinks it's found the next frontier in preventing heart attacks. Novartis , Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut